This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Combination Osteogenic Therapy in Established Osteoporosis

This study has been completed.
Information provided by:
VA Office of Research and Development Identifier:
First received: July 3, 2001
Last updated: January 20, 2009
Last verified: December 2004
This study is designed to determine if combining parathyroid (PTH 1-34) with fluoride (MFPSR) therapy in a cyclic treatment regimen will: (1) produce a greater increase in bone density of the spine than would be produced by either treatment alone; (2) prevent the resistance (i.e., decreased bone formation and no further increase in bone density) that is observed within 18-24 months of PTH therapy; (3) eliminate the calcium deficiency and osteomalacia that can occur with fluoride; (4) prevent excessive bone fluoride content; and (5) result in an increase in bone density which is maintained after treatment is discontinued.

Condition Intervention Phase
Osteoporosis, Post-Menopausal Drug: PTH 1-34 Drug: MFPSR-fluoride Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Masking: Open Label
Primary Purpose: Treatment
Official Title: Combination Osteogenic Therapy in Established Osteoporosis

Resource links provided by NLM:

Further study details as provided by VA Office of Research and Development:

Study Start Date: November 1998
Estimated Study Completion Date: October 2003
Detailed Description:
This is a 3-yr, single center, open label, active controlled, randomized study of approximately 99 postmenopausal females with osteoporosis of spine or femoral neck. Patients will be assigned to 1 of 3 groups: 1) PTH 1-34; 2) Fluoride; 3) PTH and fluoride. The treatment period is 3 years with 3-month cycles of therapy. PTH will be administered subcutaneously by injection 600 units daily for 28 days the first month of each 3-month cycle. Fluoride will be administered orally one 76mg tablet twice daily (providing 20 mg fluoride/day), during the last 2 months of each cycle. Calcium will be provided 800mg/day during month 1 and 1500-2000mg for months 2 and 3 of each cycle.

Ages Eligible for Study:   60 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
  • Female, aged 60-80,
  • Postmenopausal greater than or equal to 5 years,
  • BMD -2.5 to -4.0 at lumbar spine or femoral neck and one standard deviation below young adult mean in the other site, or -2.0 with fracture.
  • Vertebral fracture 0-1.

Exclusion Criteria:

  • More than 1 vertebral fracture in lumbar spine or more than 4 fracture in the T-L spine.
  • Weight less than 45 kg or more than 80 kg, or more than 25% above ideal body weight.
  • Present cardiac disease present.
  • Diseases or conditions known to affect bone metabolism.
  • Therapies with drugs that affect bone metabolism within 6 months.
  • Fluoride or Biophosphonates at any time.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00018447

United States, California
Jerry L. Pettis Memorial Veterans Medical Center
Loma Linda, California, United States, 92357
Sponsors and Collaborators
VA Office of Research and Development
  More Information Identifier: NCT00018447     History of Changes
Other Study ID Numbers: ENDO-022-98S
Study First Received: July 3, 2001
Last Updated: January 20, 2009

Keywords provided by VA Office of Research and Development:

Additional relevant MeSH terms:
Osteoporosis, Postmenopausal
Bone Diseases, Metabolic
Bone Diseases
Musculoskeletal Diseases
Cariostatic Agents
Protective Agents
Physiological Effects of Drugs processed this record on July 25, 2017